Current Studies

​​​​To enroll in or obtain more information about these clinical trials, please call the Screening Coordinator at (619) 543-3740 or email the AVRC at

The AVRC is actively recruiting for the following studies on COVID-19, HIV, and sexual health (last updated 10OCT2023):



Several treatments are now being used for COVID-19. However, new treatment options are needed to help people recover faster from COVID-19. The SCORPIO-HR study is a clinical research study looking at whether an investigational drug for COVID-19 can help resolve COVID-19 symptoms faster in people who have tested positive.

Eligibility requirements include:

  • Age 18+ years of age.
  • Have had a positive diagnosis of COVID-19 within the past 3 days.
  • Are experiencing COVID-19 symptoms such as coughing, shortness of breath, feeling feverish, fatigue, nausea, chills, headaches, or sore throat, among others, within the past 3 days (with one or more symptoms ongoing).


ACTG 5321 (AHRC)

Studying differences and changes over time in HIV reservoirs (groups of HIV-infected cells that 'hide' from anti-HIV medications) and attempting to answer questions about the ways that HIV infection is controlled. This may have to do with a person’s viral load and CD4 count, when they started their anti-HIV medications, and genetic factors.

Eligibility requirements include

You must be in one of the following two groups:
      • ​People who took anti-HIV drugs in the past to control their HIV but who have not been taking any anti-HIV drugs for at least 6 months and whose HIV is still very low or not detectable (meaning that it cannot be measured by standard tests).
      • People who are taking anti-HIV drugs but whose HIV level is still detectable (meaning that it can be measured by standard tests).

You must also:
      • Be a person with HIV, ≥ 18 years of age.
      • Have never stopped your anti-HIV medications for more than 3 weeks.
      • Have no active hepatitis B or C infection, an autoimmune, disorder or a condition requiring steroid therapy.


This study is investigating if Long-Acting (LA) Injectable ART will be more successful for people who are non-adherent to their HIV medications than oral standard of care regimens. The main advantages of LA ART in this population include infrequent dosing and directly observed therapy. A challenge for participants is that, to be eligible to receive LA ART, they will need to attain virologic suppression through adherence to their SOC oral medications.

Eligibility requirements include:
  • ​​Living with HIV and ages 18 and older.
  • Wiling to receive injections and no previous use of Cabotegravir.
  • Evidence of non-adherence to HIV medications, as defined by: poor virologic response within the last 18 months in individuals who have been prescribed ART for at least 6 consecutive months OR lost to clinical follow-up within the last 18 months with ART non-adherence for >6 consecutive months.

ACTG 5386 (N-803 with or without bNAbs for HIV-1 control in participants living with HIV-1 on suppressive ART)

Scientists are looking for ways to effectively clear HIV that rests in areas of the body where standard antiretroviral treatment (ART) is unable to reach. IL-15 superagonist (N-803) appears to reactivate HIV that is "asleep" and is also thought to increase the body's natural immune response to HIV. Broadly neutralizing antibodies (bNAbs), such as 10-1074 and VRC07-523LS, have been shown to control growth of HIV in the blood and to increase the body's immune response to HIV. N-803 alone or in combination with bNAbs may provide greater control of HIV than previous efforts. 

Eligibility requirements include:
    • Living with HIV and age 18 to 70 years old.
    • Be willing to take a superagonist and broadly neutralizing antibodies and complete study-related tests.
    • Be willing to temporarily stop taking antiretrovirals or ART.

ACTG 5391 (Do IT)

This research study is trying to find out if PWH who are obese (BMI greater than or equal to 30 kg/m2) and are on a treatment regimen that includes an INSTI in combination with TAF/FTC (or TAF/3TC) could gain less weight, or maybe lose weight, after switching to a regimen containing doravirine (DOR) with either TAF/FTC (or TAF/3TC), or the related medication tenofovir disoproxil fumarate/emtricitabine (TDF/FTC [or TDF/3TC]). DOR is an FDA-approved antiretroviral drug for the treatment of HIV-1 and a member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) medication class. In multiple studies, DOR was shown to be just as effective as INSTI medications for treating HIV. In multiple studies, DOR was shown to be just as effective as INSTI medications for treating HIV.​

Eligibility requirements:
  • ​Living with HIV and age 18 years or older.
  • Currently on an Integrase Inhibitor (INSTI) containing regimen (BIC, DTG or RAL), with more than 48 weeks INSTI+TAF/FTC (or TAF/3TC) dosing prior to study entry.
  • Have a body mass index (BMI) greater than or equal to 30 kg/m2.

DEPTH (Doxycycline for Emphysema in People Living with HIV​)  *NEW*

This is a research study to evaluate if the medication doxycycline, a commonly used antibiotic, can slow the damage to the lungs caused by emphysema in people who also have HIV. Emphysema is more prevalent in people living with HIV and may progress faster than in HIV-negative individuals. Doxycycline is approved by the FDA to treat or prevent a variety of infections and conditions. It has not been approved to treat emphysema in people living with HIV, so the use in this study is considered investigational.

The study involves about 10 study visits over 18-20 months, including pulmonary testing at some visits, and 2 chest CT scans.

Eligibility requirements include:

  • ​​Living with HIV and stable on treatment
  • At least 30 years old, and a current or former smoker
  • Willing to take study drug (doxycycline or placebo) twice daily for 18 months
  • You do not need to be formally diagnosed with emphysema to participate.


People at the end of their lives often have a unique perspective on life, death and altruism, and may hold the keys to curing HIV. This study takes the next steps in finding a cure for HIV by understanding how reservoirs are distributed throughout the body.

Eligibility requirements include:

  • Living with HIV and age 18 years or older.
  • Agree to body tissue donation after death.
  • On treatment for HIV at the time of enrollment.Terminally-ill with less than 6 months to live.


A5418 (STOMP)

Tecovirimat (also known as TPOXX) is a drug that may help to treat infections caused by pox viruses. Tecovirimat is approved by the Food and Drug Administration (FDA) to treat smallpox in adults and children. Its use in this study is considered investigational. An investigational use is one that has not been approved by the FDA. Tecovirimat has been approved for use in this study based only on data from animals. We don’t know for sure if it works to treat any infections in people. The FDA has reviewed information on tecovirimat and determined that tecovirimat may help treat infection, including serious or potentially life-threatening disease from poxviruses. 

We are doing this study to see if tecovirimat is safe and whether it helps treat MPOX in people.

Eligibility requirements include:
  • Laboratory-confirmed or presumptive MPOX infection.
  • MPOX illness of less than 14 days duration.
  • At least one active (not yet scabbed) skin lesion, mouth lesion, or proctitis (inflammation of the lining of the rectum) with or without visible ulcers.

Medical Diagnostics


This research study seeks to assess the performance of an at-home test for two sexually transmitted infections: Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG).  Eligible participants will receive up to $200 as compensation for one in-person visit that will last about 2 hours.  ​

Eligibility requirements include:

  • ​You are 18 years or older,   
  • You have symptoms of chlamydia or gonorrhea, OR,   
  • You are without symptoms and have any ONE of the following:  
    • ​A previous or coexisting sexually transmitted infection (STI) 
    • A new sex partner  
    • A sex partner with concurrent partners  
    • Inconsistent condom use when not in a mutually monogamous relationship  
    • A sex partner who recently tested positive for an STI  
    • A history of exchanging sex for money or drugs ​


This research study seeks to test the performance of an investigational blood analyzer to make routine health tests convenient and get results fast. Eligible participants will receive $40 as compensation.

Eligibility requirements include:

  • You are at least 18 years old.
  • You can attend one in-person visit.
  • You can provide a blood donation.

Sexual Health (for HIV-negative individuals)


We are conducting a clinical study to see whether an investigational twice-a-year injection medication can help reduce the risk of getting HIV from sex.

Eligibility requirements include​:

  • You are at least 18 years old.
  • You haven't been tested for HIV in the past 3 months.
  • You are sexually active and having receptive anal sex.

To enroll in or obtain more information about these clinical trials, please call the Screening Coordinator at (619) 543-3740 or email the AVRC at